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Abstract  
Background: Chronic infections and cardiac dysfunction are risk factors for stroke. We 
hypothesized that blood biomarkers of infection (procalcitonin, or PCT) and cardiac 
dysfunction (midregional pro-atrial natriuretic peptide, or MR-proANP), previously 
associated with small vessel stroke and cardioembolic stroke are also associated with 
subclinical cerebrovascular damage (SCVD), including silent brain infarcts (SBI) and white 
matter hyperintensity volume (WMHV). 
Methods: The Northern Manhattan Study was designed to assess risk factors for incident 
vascular disease in a multiethnic cohort. A subsample underwent brain MRI and had blood 
samples available for biomarker measurement (n=1178). We used logistic regression models 
to estimate the odds ratios and 95% confidence intervals (OR, 95%CI) for the association of 
these biomarkers with SBI after adjusting for demographic, behavioral, and medical risk 
factors. We used linear regression to assess associations with logWMHV.   
Results: Mean age was 70 ±9 years; 60% were women, 66% Hispanic, 17% black, 15% 
white. After adjusting for risk factors, subjects with PCT or MR-proANP in the top quartile, 
compared to the lowest quartile were more likely to have SBI (adjusted OR for PCT 2.2, 
95%CI 1.3-3.7; for MR-proANP 3.3, 95%CI 1.7-6.3) and increased WMHV (adjusted mean 
change in logWMHV for PCT 0.29, 95%CI 0.13-0.44; for MR-proANP 0.18, 95%CI 0.004-
0.36).  
Conclusion: Higher concentrations of PCT, a marker of infection, and MR-proANP, a marker 
of cardiac dysfunction, are independently associated with SCVD. If further studies 
demonstrate an incremental value for risk-stratification, biomarker-guided primary prevention 
studies may lead to new approaches to prevent CVD.  
  
Katan 
 
 
3 
Introduction 
Subclinical cerebrovascular disease (SCVD), as manifested by subclinical brain 
infarcts (SBI) or white matter hyperintensities (WMH) visualized on MRI, has been 
associated with incident ischemic stroke1 and cognitive dysfunction and dementia2, 3.  
There is very little data on blood biomarkers and their association with SCVD, but 
such knowledge could help identify novel preventive and therapeutic targets for stroke, 
cognitive dysfunction, and dementia simultaneously. For this purpose, the measurement of 
blood biomarkers, which may indicate underlying subclinical pathological processes, could be 
an important adjunct to traditional risk assessment.  
 Chronic infections have been associated with stroke risk and cognitive impairment 
even after adjusting for other potential confounders4, 5,. Serum procalcitonin (PCT) 
concentrations correlate with the extent and severity of microbial invasion6. In a recent study 
nested within in the Northern Manhattan Study (NOMAS), PCT concentrations were 
associated specifically with small vessel stroke7.  
 Higher natriuretic peptide levels reflect severity of cardiac dysfunction 8. There is 
increasing evidence supporting the potential role of elevated natriuretic peptides as risk 
factors of cognitive impairment.9 Midregional pro-atrial natriuretic peptide (MR-proANP) has 
been shown to be associated specifically with cardioembolic stroke etiology7, 10.  
Both chronic infections and underlying cardiac dysfunction may be risk factors not 
only for overt ischemic stroke but also for SCVD. Thus we hypothesized that PCT, as a 
surrogate for bacterial infections, and MR-proANP, as a marker of cardiac dysfunction, 
previously associated with small vessel stroke and cardioembolic stroke7, respectively, would 
also be associated with MRI measures of SCVD in the ethnically diverse Northern Manhattan 
population.  
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Methods 
Study population 
NOMAS is a population-based cohort study among 3,298 initially stroke-free participants 
identified using random digit dialing with dual-frame sampling to identify telephone numbers. 
NOMAS was designed to evaluate the effects of medical, socioeconomic, and other risk 
factors on the incidence of vascular disease in a stroke-free multiethnic community cohort. 
Methods of participant recruitment, evaluation, and follow-up have been previously reported 
11. Briefly, subjects were eligible if they: (1) had never had a stroke diagnosed; (2) were over 
age 40 years; and (3) resided in Northern Manhattan in a household with a telephone. 
Participants underwent a thorough baseline examination. Standardized questions about 
vascular risk factors were adapted from the Centers for Disease Control and Prevention 
Behavioral Risk Factor Surveillance System as defined previously.12 Changes in health or 
vital status were determined through annual telephone follow-up and clinical examinations. 
The Institutional Review Boards at Columbia University Medical Center and the University 
of Miami approved the study. All participants gave informed consent to participate in the 
study. 
 
MRI Sample 
Participants included in this analysis were part of a sample recruited from the NOMAS cohort 
to undergo brain MRI scans, using the following criteria: (1) age ≥ 50 years; (2) no 
contraindications to MRI; and (3) willing to sign informed consent. To maximize recruitment, 
an additional 199 participants, who were household members of existing NOMAS 
participants (n=1091), were recruited into the MRI sample for a total of 1290 participants. 
Out of these 199 household members 29 (15%) were blood relatives. Imaging was performed 
on a 1.5T MRI system (Philips Medical Systems, Best, the Netherlands). Stored frozen serum 
samples, drawn at the time of the MRI, were available in 1178 subjects from this sub-cohort.  
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MRI examination 
 The processing of MRI scans in NOMAS has been published 13, 14. Briefly, the 
presence or absence of SBI was determined from the size, location, and imaging 
characteristics of the lesion15. Lesions were >3 mm in size with CSF density on the 
subtraction image, in a vascular distribution, and distinct from circle of Willis vessels and 
perivascular spaces if in the basal ganglia. Inter-observer agreement for SBI detection was 
93.3%16. 
 Analyses for WMHV were performed using semi-automated measurements of pixel 
distributions and mathematical modeling of pixel-intensity histograms for cerebrospinal fluid 
and brain (white and gray matter) to identify the optimal pixel-intensity threshold to 
distinguish cerebrospinal fluid from brain matter. Analyses were performed using a custom-
designed image analysis package (QUANTA 6.2 using a Sun Microsystems Ultra 5 
workstation). WMHV was calculated as percent total intracranial volume (ICV) to correct for 
differences in head size17 and log-transformed to achieve a normal distribution (log-WMHV). 
All analyses were performed blind to participant identifying information and biomarker 
measurements.  
Biomarker measurements 
 At baseline, blood samples were obtained, centrifuged, and frozen at -80°C in 1 ml 
aliquots until the time of analysis. The samples of 1178 subjects with available serum were 
shipped on dry ice to the Department of Clinical Chemistry, University Hospital of Zurich, for 
biomarker measurements. Samples were thawed at 4 °C prior to measurements and analyzed 
within one hour, thus reducing pre-analytic errors. PCT concentrations were measured using a 
sensitive assay with a detection limit of 0.007 ng/ml (B·R·A·H·M·S-us PCT sensitive 
KRYPTOR, Thermo-Scientific, BRAHMS, Germany). MR-proANP concentrations were 
measured using an immunoassay with a detection limit of 2.1 pmol/L (B·R·A·H·M·S 
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KRYPTOR, Thermo Scientific, BRAHMS, Germany). Quality control was maintained using 
standardized procedures. All testing was performed in a batched analysis, blinded to all 
clinical data. Stability at room temperature and after freezing and thawing cycles has been 
documented for both biomarkers 18, 19.  
 
Statistical Analyses 
 We calculated descriptive statistics for the clinical, demographic, and biomarker 
variables. The primary outcomes for this analysis were 1) the presence of SBI (dichotomous 
variable) and 2) WMHV (continuous variable). The main variables, PCT and MR-proANP, 
were log transformed to achieve linearity and analyzed continuously and by quartile in order 
to facilitate clinical interpretation. Odds ratios (OR, for SBI) and beta-coefficients (β, for 
WMHV) and 95% confidence intervals (95% CI) were calculated, unadjusted and adjusted for 
demographic and vascular risk factors. Covariates included predictors of ischemic stroke and 
WMHV in prior analyses in NOMAS, including age at the time of MRI, sex, race-ethnicity, 
education, and insurance status, physical activity, smoking status, moderate alcohol 
consumption, diabetes mellitus, cardiac disease including atrial fibrillation, systolic and 
diastolic blood pressure, low density lipoprotein (LDL), and high density lipoprotein (HDL). 
We also included eGFR, since these biomarkers undergo renal clearance. We assessed 
potential effect modification of the association between biomarker levels and the outcomes by 
each vascular risk factor.  
All testing was two-tailed and p<0.05 was considered statistically significant. All calculations 
were performed using SAS v9.1.3 (SAS Institute, Cary, NC).  
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Results 
Baseline characteristics 
  Demographics and clinical characteristics of the study population (n=1178) are 
summarized in Table 1.The mean age of the sample at the time of brain MRI was 69.8 +/- 8.9 
years, 60% were women, and the majority (66%) were Hispanic. Median PCT levels were 
0.0254 ug/L (IQR 0.015-0.039 ug/L) and median MR-proANP levels were 90.2 pmol/L (IQR 
62.2-132.8 pmol/L). 
 In this MRI cohort with available blood, 168 participants (15%) had at least one SBI 
and the median WMHV (WMHV/TCV*100) was 0.35% ICV (IQR 0.21-0.75 %ICV). 
Biomarker distribution according to the presence of SBI is shown in figure A and B. 
 
Association of PCT with MRI measures of SCVD 
 In the unadjusted analysis, PCT concentration was associated with prevalence of SBI 
(OR 1.32 per SD of logPCT, 95%CI 1.12-1.56). This association remained after adjusting for 
demographic and vascular risk factors (OR 1.25 per SD of logPCT, 95 %CI 1.03-1.50). When 
analyzed by quartiles, individuals in the top PCT quartile were more likely to have SBI 
compared to those in the lowest quartile (unadjusted OR 2.44, 95% CI 1.51-3.96) (Table 2). 
After adjusting for demographic and vascular risk factors, those with PCT in the top quartile, 
compared to the lowest quartile, remained more likely to have SBI  (adjusted OR 2.16, 95% 
CI 1.26-3.69; Table 2). We found no effect modification by vascular risk factors. 
 Greater PCT concentration was also associated with greater WMHV (unadjusted mean 
change in logWMHV per SD of logPCT 0.18, 95%CI 0.13-0.24), and this association 
remained after adjusting for demographic as well as for vascular risk factors (adjusted mean 
change in logWMHV per SD of logPCT 0.10, 95%CI 0.04-0.15). Individuals in the top PCT 
quartile, compared to the lowest quartile, also had greater WMHV (unadjusted mean change 
in logWMHV 0.52, 95%CI 0.37-0.68). This association remained after adjusting for 
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demographic as well as vascular risk factors (adjusted mean change in logWMHV 0.29, 
95%CI 0.13-0.44, Table 3). We found no effect modification by vascular risk factors.  
 
Association of MR-proANP with measures of SCVD 
In the unadjusted analysis MR-proANP concentration was associated with SBI (OR 1.67 per 
SD of log MR-proANP, 95%CI 1.42-1.97); this association remained after adjusting for 
demographic and vascular risk factors (OR 1.54 per SD of log MR-proANP, 95 %CI 1.22-
1.94). When analyzed by quartiles, individuals in the top MR-proANP quartile were more 
likely to have SBI compared to those in the lowest quartile (unadjusted OR 3.99, 95% CI 
2.39-6.65). This association remained after adjusting for demographic and vascular risk 
factors (adjusted OR 3.31, 95% CI 1.74-6.32; Table 2). We found no effect modification by 
vascular risk factors. 
 MR-proANP concentration was further associated with WMHV (unadjusted mean 
change in logWMHV per SD of logMR-proANP 0.28, 95%CI 0.22-0.33), though this linear 
association was no longer statistically significant after adjusting for demographic and vascular 
risk factors (adjusted mean change in logWMHV per SD of logMR-proANP 0.05, 95%CI -
0.01-0.12). When analyzed by quartiles, participants with MR-proANP levels in the top 
quartile had greater WMHV than those in the lowest quartile (unadjusted mean change in 
logWMHV 0.74, 95%CI 0.59-0.90) and this persisted after adjusting for sociodemographic 
and vascular risk factors, though the effect was attenuated (adjusted mean change in 
logWMHV 0.18, 95%CI 0.004-0.36, Table 3). We found no effect modification by baseline 
vascular risk factors. 
 
Discussion 
In this urban, multiethnic, population-based sample, PCT, a marker of bacterial 
infection, and MR-proANP, a marker for cardiac dysfunction, were each independently 
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associated with two measures of subclinical cerebrovascular disease, SBI and WMHV. 
However, the association of MR-proANP concentrations with WMHV was less pronounced 
compared to the association with SBI. 
 Silent brain infarction serves as an imaging biomarker of vascular brain health. SBI 
has been associated with traditional vascular risk factors, as well as with future clinical 
stroke20, cognitive decline, and dementia3, 21. The independent association of SBI with future 
stroke, however, after adjusting for vascular risk factors, suggests that SBIs reflect either an 
overall effect of uncontrolled vascular risk factors better than the presence or absence of each 
individual factor, or that other, yet unknown, factors play a role in the association with stroke 
and dementia. These unknown factors may include underlying chronic infection, measured by 
PCT, or subclinical cardiac disease, measured by MR-proANP.   
 Recent findings in patients with cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy (CADASIL) suggest that mechanisms of SBI 
and white matter hyperintensities are intimately connected22. In these patients the majority of 
incident lacunes developed proximal to a white matter hyperintensity along the course of 
perforating vessels supplying the respective brain region22. With the caveat that not all SBI or 
WMH defined by MRI are definitely of vascular origin, this finding provides indirect 
evidence that both imaging markers are good surrogates of small vessel disease including 
consecutive overt strokes and eventually vascular dementia.   
Procalcitonin was first shown in the early 1990s to be a sepsis-induced protein 
detectable in patient plasma23. Currently PCT is used to guide antibiotic use in patients with 
lower respiratory tract infections.24 If PCT concentrations are above 0.5 ug/L, acute bacterial 
pneumonia is very likely, and antibiotic treatment is strongly recommended. PCT synthesis 
and secretion are up-regulated by lipopolysaccharides and certain bacteria-specific pro-
inflammatory mediators (for example, interleukin-1β, tumor necrosis factor-α, and 
interleukin-6), and are down-regulated as concentrations of these substances decrease during 
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recovery from infection 25,26.  Interestingly, a polymorphism in the gene encoding the 
monocyte receptor for bacterial lipopolysaccharide (CD14) was specifically associated with 
large atherosclerotic and small vessel stroke, but not other types of stroke27. In a pilot case-
cohort analysis in NOMAS we found an association of PCT with stroke risk, and in particular 
with small vessel stroke . The biological role of PCT in vivo at low concentrations in stroke-
free people has so far been largely unexplored. Based on our data from this and our prior 
analysis7 we propose that even low concentrations of PCT may reflect ongoing subclinical 
inflammatory processes triggered by bacterial endotoxins, which in turn contribute to the 
small vessel damage that causes some SCVD,28 29 as well as overt small vessel stroke. 
Brain natriuretic peptide (BNP) and N-terminal pro-B-natriuretic peptide 
(NTproBNP), as members of the family of the natriuretic peptides, have also been associated 
with incident stroke in some studies,30, 31 as well as with WMH and SBI in the Atherosclerosis 
Risk in Communities (ARIC) study. Additionally, higher NT-proBNP concentrations were 
prospectively associated with increased incident SBIs and WMH progression over 8 years of 
follow-up32. Our search did not reveal prior studies of MR-proANP, another member of the 
family of the natriuretic peptides, in relation to SBI or WMHV. Concerning mortality in 
patients with chronic heart failure, MR-proANP outperformed BNP and NT-proBNP. The 
proportion of explained variance showed that MR-proANP (4.36%) was a significantly 
stronger predictor of death than either NT-proBNP (2.47%, p < 0.0001) or BNP (2.42%, p < 
0.0001). Both a new assay technology and the high biological stability of MR-proANP are 
potential explanations for these findings33. The pathophysiological mechanism explaining the 
independent associations of MR-proANP with SBI and to a lesser extent with WMHV in our 
study needs confirmation. We hypothesize that high MR-proANP concentrations indicate the 
presence of underlying early atrial pathology, thus leading to silent strokes, but only to a 
slight increase in WMHV, which is less likely to have exclusively a cardioembolic etiology 
and could also reflect effects such as relative hypoperfusion primarily based on other 
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pathomechanisms. White matter lesions can occur with acute34 and also chronic cerebral 
ischemia35, but non-arteriolar and non-ischemic mechanisms for WMH have also been 
proposed36, including venous sclerosis with subsequent venous hypertension37, all of which 
are less prone to be associated with an underlying cardiac disease. The association of MR-
proANP with WMHV, compared to the association with SBI, was thus more attenuated after 
adjustment, pointing to the fact that other comorbidities such as smoking are probably more 
important risk factors for an increase in WMHV.  
  Our study has limitations. Our cross-sectional analysis does not allow for determining 
causal relationships, and we cannot exclude the possibility of residual confounding. Our 
findings require replication in an external sample to ensure validity. Also, repeated 
measurements of the selected biomarkers and their change over time may be a better indicator 
of SCVD than levels measured at a single baseline point. Further, we did not perform direct 
comparison of PCT with other markers of infection or inflammation, such as C-reactive-
protein, nor did we compare MRproANP with NT-proBNP. However in a previous study of 
high-sensitivity CRP in NOMAS, we did not find a significant independent association of 
CRP with incident stroke38. Similarly, in a prior analysis of a subgroup of the NOMAS MRI 
cohort including different inflammatory markers, CRP was not independently associated with 
silent infarcts or white matter disease after adjusting for other risk factors and biomarkers39. 
Finally, the blood samples were stored at -80 °C for several years, which could lead to some 
protein degradation. Degradation would, however have affected subjects with and without 
SBI similarly, and probably would have biased our results toward the null.  
The strengths of this study include the population-based multiethnic cohort, including 
a large proportion of Hispanics who are frequently underrepresented in other cohort studies, 
and detailed clinical information on participants, permitting us to adjust for numerous 
potential covariates. Finally, this study provides prospectively planned imaging sequences to 
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specifically assess subclinical cerebrovascular disease as an important risk factor of overt 
stroke and dementia.  
In conclusion, we report associations of PCT and MR-proANP with SCVD. The 
present study was aimed at identifying novel markers reflecting different potential 
mechanisms that may contribute to subclinical vascular disease. Whether these markers will 
be of clinical use in the future remains to be determined. If, however, other studies confirm 
these associations, and if further studies show an incremental value for risk stratification, we 
may in the future base the selection for specific primary preventive interventions concerning 
underlying subclinical infections and heart disease on these biomarker levels. Given the 
multiple adverse health outcomes associated with SCVD in older individuals these biomarker-
guided interventions may have a clinically relevant impact and may be beneficial even for the 
prevention of both stroke and cognitive impairment. 
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Figure legend 
 
Figure A: Distribution of logPCT concentrations according to the presence of silent brain 
infarcts (SBI). 
 
Figure B: Distribution of logMRproANP concentrations according to the presence of silent 
brain infarcts (SBI). 
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Table 1. Baseline demographics and risk factors of the Northern Manhattan Study 
Magnetic Resonance Imaging subsample with serum samples available for this analysis 
(n = 1178) 
 
Socio-demographic characteristics mean (+/- SD) or median (IQR); n (%) 
Age at the time of MRI in years 69.8 (+/-8.9) 
Women  707 (60%) 
Race-Ethnicity  
 Hispanic  780 (66%) 
 Non-Hispanic Black   200 (17%) 
 Non-Hispanic White 171 (15%) 
 Other 25 (2%) 
Less than high school education  632 (54%) 
Medicaid or no insurance  555 (47%) 
Medical Co-morbidities  
Current tobacco use  
   
 184 (16%) 
Moderate alcohol use* 
  
 484 (41%) 
Mean systolic blood pressures in mmHg 137 (+/- 8)  
Mean diastolic blood pressures in mmHg 78 (+/-10) 
Estimated glomerular filtration rate 78 (+/-20) 
Cardiac Disease †  
Diabetes mellitus ‡ 228 (19 %) 
Laboratory parameters    
High-density lipoprotein mg/dl 53.4 (+/-17) 
Low-density lipoprotein mg/dl 115 (+/-35.3) 
Procalcitonin ug/L 0.025(0.015-0.039) 
MR-proANP pmol/L  90.2 (62.2-132.8) 
 
*Moderate alcohol use = <2 servings of alcohol per day (reference all other groups) 
† Cardiac disease= coronary artery disease, congestive heart failure and atrial fibrillation  
‡Diabetes mellitus was defined as fasting blood glucose > 126 mg/dl, the subject’s self-report 
of diabetes mellitus, or insulin and/or hypoglycemic agent use. 
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Table 2. Association of biomarkers with silent brain infarcts 
Parameter Unadjusted 
OR (95% CI) 
Model 1* 
OR (95% CI) 
Model 2** 
OR (95% CI) 
PCT 
First quartile  Reference 
Second quartile  1.5 (0.9-2.6) 1.4 (0.8-2.4) 1.4 (0.8 - 2.4) 
Third quartile 1.4 (0.9-2.4) 1.3 (0.7-2.2) 1.2 (0.7 - 2.2) 
Fourth quartile 2.4 (1.5-4.0) 1.9 (1.1-3.2) 2.2 (1.3 - 3.7) 
MR-proANP 
First quartile  Reference 
Second quartile  1.3 (0.8-2.4) 1.4 (0.8-2.6) 1.5 (0.8 - 2.8) 
Third quartile 2.3 (1.4-4.0) 2.0 (1.1-3.6) 1.9 (1.1 - 3.6) 
Fourth quartile 4.0 (2.4-6.7) 2.8 (1.5-5.2) 3.3 (1.7 - 6.3) 
*Model 1; adjusted for age, gender, race-ethnicity, education and insurance status. 
** Model 2; adjusted for covariates in Model 1 plus physical activity, smoking status, 
moderate alcohol consumption, cardiac disease, diabetes mellitus, systolic and diastolic blood 
pressure, low density lipoprotein (LDL), high density lipoprotein (HDL), estimated 
glomerular-filtration-rate (eGFR). 
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Table 3. Association of top quartile of PCT and MR-proANP with log-total  
white matter hyperintensity volume 
 
Parameter Univariate analysis 
parameter  
estimate (95% CI) 
 
Model 1*    
parameter 
estimate (95% CI) 
Model 2** 
parameter  
estimate (95% CI) 
PCT 
First quartile  Reference 
Second quartile  0.20 (0.04-0.35) 0.08 (-0.06-0.22) 0.09 (-0.06-0.23) 
Third quartile 0.31 (0.15-0.46) 0.21 (0.06-0.35) 0.19 (0.05-0.34) 
Fourth quartile 0.52 (0.37-0.68) 0.29 (0.15-0. 44) 0.29 (0.13-0.44) 
MR-proANP 
First quartile  Reference 
Second quartile  0.08 (-0.07-0.23) -0.02 (-0.16-0.13) -0.03 (-0.17-0.12) 
Third quartile 0.29 (0.14-0.44) 0.00 (-0.15-0.15) -0.01 (-0.16-0.15) 
Fourth quartile 0.74 (0.59-0.90) 0.22 (0.06-0.39) 0.18 (0.004-0.36) 
 
*Model 1; adjusted for age, gender, race/ethnicity, education and insurance status. 
**Model 2; adjusted for age, gender, race/ethnicity, education, insurances status, physical 
activity, smoking status, moderate alcohol consumption, cardiac disease, diabetes mellitus, 
systolic and diastolic blood pressure, low density lipoprotein (LDL), high density lipoprotein 
(HDL), estimated glomerular-filtration-rate (eGFR). 
 
